A Phase 2 interventional study of Fenofibrate and Placebo in Diabetic Nephropathies, sponsored by Alessandro Doria. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Alessandro Doria · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.
Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 89th largest by enrollment of the 120 interventional ones that give a count, is one of 11 that started in 2022, is one of 54 in phase 2, and was the 116th registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18–75
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
Seattle Children's Hospital · Sites in United States
Ages 14–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 61 · Phase 3 16 · Phase 4 10
First in 1981; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 79 across the 120 interventional studies, 175 across the 31 observational. Of the 115 that completed or were terminated, 46 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 153 have an industry lead sponsor. The 10 most frequent:
Alessandro Doria is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Alessandro Doria has 3 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetic Nephropathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05759468Brigham and Women's HospitalNAD Augmentation in Diabetes Kidney Disease | 2026-11-30 |
| NCT07022418Medical University of South CarolinaFormoterol in Diabetes | 2026-12 |
| NCT04802395Renalytix AI, Inc.Real World Evidence Clinical Utility Study of KidneyIntelX | 2026-12-01 |
| NCT05507892University of Colorado, DenverRenal Mechanism of SGLT2 Inhibition | 2026-12-15 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 153 studies in Diabetic Nephropathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetic kidney disease remains the leading cause of end-stage kidney disease (ESKD), rising in frequency in parallel with the epidemic of diabetes worldwide. The estimated lifetime risk of kidney disease in persons with type 1 diabetes (T1D) has been reported to be as high as 50-70%, although risk may be lower in excellent care environments. Two previous studies have suggested that a generic drug used to lower fats in blood (fenofibrate) may protect the kidney from damage due to diabetes. These data, however, were obtained among people with type 2 diabetes with clinical characteristics optimized for cardiovascular studies. Thus, a clinical trial specifically designed to evaluate the effects on the kidney is required to firmly show that this drug can prevent kidney damage in T1D. The goals of the present pilot study are to demonstrate the feasibility of such trial, gather essential information for designing and planning this study, and generate preliminary data. To this end, 40 participants with T1D and early-to-moderate diabetic kidney disease (DKD), at high risk of ESKD, will be enrolled at two clinical sites and assigned in a 1:1 ratio to treatment with fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and at the end of the study to evaluate the effect of fenofibrate.
Despite improvements in the past 20 years in glycemic and blood pressure control, and the introduction of "reno-protective" drugs such as renin-angiotensin system blockers (RASB), the overall incidence of end-stage kidney disease (ESKD) in type 1 diabetes (T1D) remains high. To seek new treatments to prevent diabetic kidney disease (DKD) and/or slow its progression to ESKD in T1D, the investigators have established a unique consortium of high-quality academic centers, which has been named PERL (Preventing Early Renal Function Loss in Diabetes) to emphasize the focus on intervening relatively early in the course of DKD in T1D, when renal damage can more likely be slowed or stopped. Findings from the FIELD and ACCORD trials suggest a reno-protective effect of the PPAR-alpha agonist fenofibrate, raising the exciting possibility of using this inexpensive generic drug to prevent GFR decline in persons with T1D. These data, however, were obtained through post-hoc analyses of type 2 diabetes (T2D) populations with clinical characteristics optimized for CVD studies. Thus, a clinical trial specifically designed to evaluate effects on GFR decline is required to firmly establish a DKD indication for fenofibrate in T1D. As a first step, the investigators are conducting a pilot study including 40 participants with T1D and early-to-moderate DKD, at high risk of ESKD, who will be enrolled at two of the PERL sites and randomized in a 1:1 ratio to treatment with fenofibrate or placebo for 18 months, followed by a two-month washout. The goal of this pilot study are to:
The results of this pilot will allow the investigators to seek support for a pivotal trial to establish a kidney indication for fenofibrate in T1D.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
Drug: Fenofibrate
Inactive tablets identical to fenofibrate
Other: Placebo
145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
Inactive tablets identical to fenofibrate
Baseline-adjusted iGFR at 8 Weeks After Randomization
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted iGFR at the End of the Drug Wash-out Period
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value
Time frame: 84 weeks after randomization
Baseline-adjusted Serum Levels of CD160 at the End of the Drug-wash-out Period (Week 84).
CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks after randomization
Baseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).
CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).
DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).
EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).
EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).
EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).
GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).
IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).
KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).
LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).
LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).
PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).
PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).
RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).
SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).
TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).
TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).
TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).
TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).
TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).
WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 84 weeks from randomization
Baseline-adjusted eGFR-SCr at 8 Weeks After Randomization
GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted eGFR-CysC at 8 Weeks After Randomization
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted uAER at 8 Weeks After Randomization
Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted Creatinine Clearance at 8 Weeks After Randomization
Creatinine clearance (ml/min) based on overnight urine collection, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted ERPF at 8 Weeks After Randomization
Effective renal plasma flow (ml/min) measured by means of para-aminohippurate infusion, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted Afferent Renal Arteriolar Resistance at 8 Weeks After Randomization
Afferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted Efferent Renal Arteriolar Resistance at 8 Weeks After Randomization
Efferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted Glomerular Hydrostatic Pressure at 8 Weeks After Randomization
Glomerular hydrostatic pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted Glomerular Filtration Pressure at 8 Weeks After Randomization
Glomerular filtration pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value
Time frame: 8 weeks after randomization
Baseline-adjusted eGFR-SCr at the End of the Wash-out Period
GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
Time frame: 84 weeks after randomization
Baseline-adjusted eGFR-CysC at the End of the Wash-out Period
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
Time frame: 84 weeks after randomization
Baseline-adjusted uAER at the End of the Wash-out Period
Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value
Time frame: 84 weeks after randomization
Baseline-adjusted iGFR at the End of Treatment
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value
Time frame: 76 weeks after randomization
Baseline-adjusted eGFR-SCr at the End of Treatment
GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
Time frame: 76 weeks after randomization
Baseline-adjusted eGFR-CysC at the End of Treatment
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
Time frame: 76 weeks after randomization
Baseline-adjusted uAER at the End of Treatment
Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value
Time frame: 76 weeks after randomization
Week 8-adjusted iGFR at the End of Treatment
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its value at week 8
Time frame: 76 weeks after randomization
Week 8-adjusted eGFR-SCr at the End of Treatment
GFR estimated from serum creatine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8
Time frame: 76 weeks from randomization
Week 8-adjusted eGFR-CysC at the End of Treatment
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8
Time frame: 76 weeks after randomization
Week 8-adjusted uAER at the End of Treatment
Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its value at week 8
Time frame: 76 weeks after randomization
eGFR-SCr Trajectory
Trajectory of GFR estimated from serum creatinine (ml/min/1.73 m2/year) using the CKD-EPI equation
Time frame: 8 to 76 weeks from randomization
eGFR-SCys Trajectory
Trajectory of GFR estimated from serum cystatin C (ml/min/1.73 m2/year) using the CKD-EPI equation
Time frame: 8 to 76 weeks from randomization
Baseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).
CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).
CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).
DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).
EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).
EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).
EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).
GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).
IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).
KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).
LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).
LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).
PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).
PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).
RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).
SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).
TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).
TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).
TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).
TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).
TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Baseline-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).
WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).
CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).
CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).
DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).
EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).
EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).
EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).
GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).
IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).
KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).
LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).
LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).
PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).
PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).
RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).
SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).
TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).
TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).
TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).
TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).
TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Week 8-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).
WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
Time frame: 76 weeks after randomization
Participants were enrolled at two locations (Joslin Diabetes Center, Boston, MA and U. of Michigan, Ann Arbor, MI
| Milestone | Fenofibrate | Placebo |
|---|---|---|
| Started | 17 | 18 |
| Completed | 16 | 17 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Fenofibrate | Placebo |
|---|---|---|
| Started | 16 | 17 |
| Completed | 10 | 13 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Enrolled in abbreviated protocol ending at week 8 | 1 | 2 |
| Withdrew: Early study site closure | 1 | 1 |
| Milestone | Fenofibrate | Placebo |
|---|---|---|
| Started | 10 | 13 |
| Completed | 10 | 11 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted iGFR at 8 Weeks After Randomization | 57.9 (55.3 to 60.4) | 63.1 (60.6 to 65.6) |
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted iGFR at the End of the Drug Wash-out Period | 62.4 (56.7 to 68.2) | 61.9 (56.4 to 67.5) |
GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted eGFR-SCr at 8 Weeks After Randomization | 61.0 (57.3 to 64.8) | 70.3 (66.6 to 73.9) |
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted eGFR-CysC at 8 Weeks After Randomization | 56.6 (52.8 to 60.4) | 60.8 (57.1 to 64.5) |
Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value
| μg/min | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted uAER at 8 Weeks After Randomization | 83.1 (62.2 to 111.0) | 128.1 (95.2 to 172.4) |
Creatinine clearance (ml/min) based on overnight urine collection, adjusted by its baseline value
| ml/min | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Creatinine Clearance at 8 Weeks After Randomization | 95.4 (79.8 to 111.0) | 93.8 (77.6 to 110) |
Effective renal plasma flow (ml/min) measured by means of para-aminohippurate infusion, adjusted by its baseline value
| ml/min/1.73 m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted ERPF at 8 Weeks After Randomization | 561.6 (483.4 to 639.8) | 501.2 (420.6 to 581.7) |
Afferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value
| dyne/s/cm5 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Afferent Renal Arteriolar Resistance at 8 Weeks After Randomization | 4396 (3732 to 5060) | 4234 (3548 to 4920) |
Efferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value
| dyne/sec/cm5 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Efferent Renal Arteriolar Resistance at 8 Weeks After Randomization | 1167 (1015 to 1320) | 1312 (1156 to 1467) |
Glomerular hydrostatic pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value
| (mmHg) | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Glomerular Hydrostatic Pressure at 8 Weeks After Randomization | 11.1 (10.6 to 11.6) | 12.1 (11.7 to 12.6) |
Glomerular filtration pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value
| mmHg | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Glomerular Filtration Pressure at 8 Weeks After Randomization | 46.6 (46.0 to 47.2) | 48.0 (47.4 to 48.7) |
GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted eGFR-SCr at the End of the Wash-out Period | 69.4 (63.1 to 75.7) | 69.9 (64.2 to 75.7) |
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted eGFR-CysC at the End of the Wash-out Period | 59.2 (53.2 to 65.1) | 58.2 (52.9 to 63.6) |
Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value
| μg/min | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted uAER at the End of the Wash-out Period | 110.5 (52.3 to 233.1) | 103.5 (52.0 to 206.1) |
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value
| ml/min /1.73 m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted iGFR at the End of Treatment | 56.6 (51.0 to 62.2) | 61.9 (56.8 to 66.9) |
GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted eGFR-SCr at the End of Treatment | 56.2 (49.4 to 63.0) | 67.9 (62.0 to 73.8) |
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted eGFR-CysC at the End of Treatment | 53.7 (47.1 to 60.2) | 58.0 (52.5 to 63.6) |
Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value
| μg/min | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted uAER at the End of Treatment | 83.2 (40.7 to 170.4) | 131.4 (68.1 to 253.5) |
GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its value at week 8
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted iGFR at the End of Treatment | 61.3 (56.0 to 66.7) | 59.9 (55.3 to 64.5) |
GFR estimated from serum creatine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted eGFR-SCr at the End of Treatment | 61.6 (56.0 to 67.1) | 64.6 (59.9 to 69.2) |
GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8
| ml/min/1.73m2 | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted eGFR-CysC at the End of Treatment | 56.5 (49.1 to 63.8) | 57.1 (51.0 to 63.2) |
Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its value at week 8
| μg/min | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted uAER at the End of Treatment | 110.3 (55.5 to 219.1) | 111.3 (59.8 to 207.2) |
Trajectory of GFR estimated from serum creatinine (ml/min/1.73 m2/year) using the CKD-EPI equation
| ml/min/1.73m2/year | Fenofibrate | Placebo |
|---|---|---|
| eGFR-SCr Trajectory | -3.6 (-8.4 to 1.2) | -3.6 (-6.8 to -0.5) |
Trajectory of GFR estimated from serum cystatin C (ml/min/1.73 m2/year) using the CKD-EPI equation
| ml/min/1.73m2/year | Fenofibrate | Placebo |
|---|---|---|
| eGFR-SCys Trajectory | -3.3 (-7.7 to 1.2) | -3.8 (-8.0 to 0.6) |
CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of CD160 at the End of the Drug-wash-out Period (Week 84). | 82.4 (70.6 to 94.2) | 85.0 (74.3 to 95.6) |
CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84). | 163.2 (138.4 to 188.1) | 168.4 (146.3 to 190.5) |
DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84). | 1511.0 (1347.8 to 1674.2) | 1592.9 (1445.9 to 1739.9) |
EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84). | 14.8 (12.4 to 17.2) | 14.8 (12.6 to 17.0) |
EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84). | 95.5 (83.1 to 107.9) | 88.2 (77.3 to 99.1) |
EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84). | 19.9 (16.4 to 23.3) | 19.3 (16.1 to 22.5) |
GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84). | 770.6 (662.1 to 879.2) | 819.1 (721.0 to 917.3) |
IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84). | 157.7 (134.9 to 180.5) | 174.4 (153.6 to 195.1) |
KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84). | 342.7 (229.3 to 456.1) | 280.4 (176.3 to 384.6) |
LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84). | 6.6 (5.3 to 7.8) | 6.5 (5.3 to 7.7) |
LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84). | 146.7 (121.7 to 171.6) | 157.6 (134.8 to 180.4) |
PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84). | 14955.3 (12287.5 to 17623.0) | 13971.7 (11557.3 to 16396.1) |
PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84). | 106.5 (93.8 to 119.2) | 119.2 (107.4 to 130.5) |
RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84). | 940.7 (803.6 to 1077.8) | 897.7 (774.4 to 1021.0) |
SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84). | 213.2 (186.6 to 239.9) | 216.4 (192.2 to 240.7) |
TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84). | 8997.9 (7846.6 to 10149.3) | 9673.4 (8651.3 to 10695.5) |
TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84). | 8863.6 (7547.4 to 10179.8) | 8963.4 (7803.7 to 10123.2) |
TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84). | 18.8 (15 to 22.6) | 21.1 (17.6 to 24.5) |
TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84). | 9.7 (7.7 to 11.8) | 10.1 (8.3 to 12.0) |
TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84). | 124.2 (106.3 to 142) | 132.2 (117.1 to 147.3) |
WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84). | 286.5 (231.0 to 341.9) | 262.0 (210.9 to 313.0) |
CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76). | 87.1 (75.7 to 98.5) | 79.8 (69.6 to 90.1) |
CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76). | 163.0 (137.1 to 188.8) | 165.1 (142.1 to 188.2) |
DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76). | 1597.0 (1363.3 to 1830.7) | 1567.4 (1356.9 to 1777.9) |
EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76). | 16.0 (13.8 to 18.3) | 14.3 (12.3 to 16.4) |
EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76). | 92.6 (81.8 to 103.5) | 81.8 (72.3 to 91.3) |
EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76). | 17.1 (-15.1 to 49.3) | 36.2 (6.5 to 65.8) |
GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76). | 853.8 (724.1 to 983.5) | 771.1 (653.8 to 888.4) |
IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76). | 157.2 (134.0 to 180.4) | 165.7 (144.6 to 186.8) |
KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76). | 330.1 (212.3 to 447.9) | 299.9 (191.7 to 408.0) |
LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76). | 6.7 (5.5 to 7.9) | 6.5 (5.4 to 7.6) |
LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76). | 154.8 (132.7 to 176.8) | 150.8 (130.7 to 171.0) |
PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76). | 16915.1 (14338.3 to 19492.0) | 12726.1 (10393.9 to 15058.2) |
PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76). | 110.2 (95.3 to 125.1) | 118.6 (105.1 to 132.1) |
RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76). | 935.5 (799.6 to 1071.4) | 876.2 (754.0 to 998.4) |
SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76). | 196.0 (163.1 to 229.0) | 203.2 (173.2 to 233.2) |
TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76). | 9539.0 (8433.1 to 10644.9) | 9576.4 (8594.6 to 10558.2) |
TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76). | 10126.1 (8202.2 to 12050.0) | 8880.8 (7185.6 to 10576.0) |
TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76). | 20.1 (16.7 to 23.6) | 20.9 (17.8 to 24.1) |
TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76). | 9.6 (8.1 to 11.1) | 9.9 (8.5 to 11.3) |
TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76). | 122.3 (96.6 to 148.1) | 134.4 (112.6 to 156.3) |
WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Baseline-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76). | 295.0 (237.9 to 352.2) | 258.3 (205.7 to 310.9) |
CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76). | 87.1 (77.7 to 96.5) | 80.4 (71.9 to 89.0) |
CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76). | 171.8 (149.9 to 193.7) | 161.8 (141.9 to 181.8) |
DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76). | 1625.0 (1464.5 to 1785.6) | 1565.8 (1418.6 to 1713.0) |
EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76). | 15.3 (13.5 to 17.2) | 14.9 (13.2 to 16.6) |
EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76). | 87.3 (79.9 to 94.7) | 85.7 (79.2 to 92.2) |
EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76). | 17.3 (-15.8 to 50.4) | 37.3 (7.0 to 67.7) |
GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76). | 831.1 (728.7 to 933.5) | 792.8 (700.1 to 885.5) |
IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76). | 156.9 (136.3 to 177.5) | 167.8 (148.9 to 186.7) |
KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76). | 336.2 (224.6 to 447.9) | 295.6 (193.2 to 398.0) |
LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76). | 6.3 (4.9 to 7.7) | 6.9 (5.6 to 8.2) |
LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76). | 151.9 (137.6 to 166.2) | 156.6 (143.5 to 169.6) |
PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76). | 15392.1 (13080.7 to 17703.6) | 13728.7 (11692.5 to 15765.0) |
PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76). | 111.7 (98.0 to 125.3) | 118.3 (105.8 to 130.8) |
RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76). | 902.0 (800.2 to 1003.8) | 911.7 (819.0 to 1004.3) |
SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76). | 192.6 (167.7 to 217.4) | 211.9 (189.3 to 234.5) |
TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76). | 9697.2 (8803.8 to 10590.6) | 9608.0 (8797.7 to 10418.3) |
TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76). | 10065.2 (8689.5 to 11440.9) | 9136.4 (7881.8 to 10391.0) |
TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76). | 20.9 (18.7 to 23.0) | 20.7 (18.7 to 22.6) |
TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76). | 9.9 (8.7 to 11.0) | 9.8 (8.7 to 10.8) |
TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76). | 128.2 (108.0 to 148.3) | 131.8 (113.7 to 149.9) |
WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.
| pg/ml | Fenofibrate | Placebo |
|---|---|---|
| Week 8-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76). | 290.8 (243.8 to 337.8) | 263.4 (220.2 to 306.6) |
Collected over In each participant, adverse event data were collected from randomization to two months after the end of pharmacological treatment, or until study discontinuation for participants who did not complete the study. This corresponds to up to 84 weeks for participants who completed the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fenofibrate | 0/17 (0%) | 5/17 (29.4%) | 14/17 (82.4%) |
| Placebo | 0/18 (0%) | 7/18 (38.9%) | 14/18 (77.8%) |
| Event | Fenofibrate | Placebo |
|---|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/17 | 2/18 |
| DehydrationMetabolism and nutrition disorders | 1/17 | 1/18 |
| DizzinessVascular disorders | 1/17 | 0/18 |
| GastroenteritisInfections and infestations | 1/17 | 0/18 |
| HypervolaemiaCardiac disorders | 1/17 | 0/18 |
| HypotensionVascular disorders | 1/17 | 0/18 |
| IridocyclitisEye disorders | 1/17 | 0/18 |
| Oedema peripheralCardiac disorders | 1/17 | 0/18 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/17 | 0/18 |
| SyncopeVascular disorders | 1/17 | 0/18 |
| Event | Fenofibrate | Placebo |
|---|---|---|
| Laboratory test abnormalInvestigations | 11/17 | 8/18 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/17 | 3/18 |
| DyspepsiaGastrointestinal disorders | 0/17 | 2/18 |
| PneumoniaInfections and infestations | 1/17 | 2/18 |
| RashSkin and subcutaneous tissue disorders | 1/17 | 2/18 |
| Acute kidney injuryRenal and urinary disorders | 1/17 | 0/18 |
| Back PainMusculoskeletal and connective tissue disorders | 1/17 | 0/18 |
| ConstipationGastrointestinal disorders | 1/17 | 0/18 |
| COVID-19Infections and infestations | 1/17 | 1/18 |
| Eye haematomaEye disorders | 1/17 | 0/18 |
| Age, Continuous(Years) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Mean | 53.8 ± 13 | 53.3 ± 13 | 53.5 ± 12.9 |
| Sex: Female, Male(Participants) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Female | 3 | 6 | 9 |
| Male | 14 | 12 | 26 |
| Race (NIH/OMB)(Participants) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 16 | 16 | 32 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Diabetes duration(years) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Mean | 40.0 ± 13 | 45.1 ± 13 | 42.6 ± 13.2 |
| BMI(Kg/m2) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Mean | 30.3 ± 4.7 | 31.5 ± 8.2 | 30.9 ± 6.6 |
| HbA1c(%) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Mean | 7.9 ± 1.8 | 7.4 ± 1.8 | 7.6 ± 1.8 |
| SBP(mmHg) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Mean | 128.3 ± 11 | 131.6 ± 13 | 130.0 ± 12 |
| DBP(mmHg) | Fenofibrate | Placebo | Total |
|---|---|---|---|
| Mean | 68.2 ± 8 | 67.5 ± 9 | 68.0 ± 9 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Final research data will be formatted as a computerized dataset at the Joslin Diabetes Center. The final dataset will include both raw data and derived variables, which will be described in documents associated with the dataset. We will maintain the primary dataset for a minimum of 3 years following closeout of the grant as stipulated under the NIH Grants Policy Statement. In agreement with NIH's policy on the sharing of data from large, NIH-sponsored studies, the data collected in the course of the study will be archived in de-identified form in an NIH Central Repository for future distribution to the scientific community.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be made available two years after completion of the study
Access criteria: Access will be governed by the NIDDK repository.
Ran from Jan 2022 to primary completion in May 2025, 39 months.
Results were first posted in Nov 2026, 1 year 6 months after primary completion.
Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenofibrate
Alessandro Doria